Instrument Inactif

Autres langues Alexion Pharmaceuticals, Inc.

Actions

ALXN

US0153511094

Produits pharmaceutiques

Autres langues

12/05	Alexion Reports Positive CALYPSO Phase III Trial Results For Eneboparatide In Adults With Hypoparathyroidism
04/12	Neurimmune Expands Collaboration with Alexion to Develop and Commercialize Fibril Depleter NI009 for AL Amyloidosis
20/11	Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US
12/11/24	Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial
25/10/24	Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million.
24/10/24	Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate
01/04/24	Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH
11/12/23	Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS
19/09/23	Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc..
08/09/23	Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases
28/07/23	Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion.
17/05/23	AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023
08/05/23	Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
30/03/23	JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease
01/12/22	AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022
17/11/22	Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics
15/11/22	Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.
11/11/22	AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China
12/10/22	Alexion Pharmaceuticals, Inc. Aims to Advance Nmosd Treatment Landscape with Exceptional Ultomiris® (Ravulizumab-Cwvz) Efficacy Data At Ectrims 2022
04/10/22	Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine
03/10/22	Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. from a group of shareholders for $68.2 million.
28/09/22	Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1
28/09/22	Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type1
26/09/22	Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis
16/09/22	Danicopan (ALXN2040) add-on to Ultomiris or Soliris met primary endpoint in ALPHA Phase III trial for patients with paroxysmal